chevron_leftBack
As of 24 April 2025, PolyPeptide Group AG has a market cap of $694.37M USD, ranking #10294 globally and #140 in Switzerland. It ranks #1001 in the Healthcare sector, and #241 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$694.37MUSD
573.48M CHF
Enterprise Value
$732.46MUSD
607.83M CHF
Revenue (TTM)
$382.57MUSD
315.97M CHF
EBITDA (TTM)
$20.66MUSD
17.15M CHF
Net Income (TTM)
-$22.22MUSD
-18.35M CHF
EBITDA Margin
5.4%
Profit Margin
-5.8%
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Juan Gonzalez
open_in_new
Employees
1,362
Founded
1952
Website
polypeptide.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | 12% | -0.7% | -33% | -40% | -38% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PPGN
ISIN: CH1110760852
Shares Out.:
Shares Outstanding:
32.996M1
Shares Float:
13.276M2
|
17.00 CHF | |
|
0AAJ
ISIN: CH1110760852
|
16.06 CHF |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
